Trastuzumab emtansine

Drug Profile

Trastuzumab emtansine

Alternative Names: Ado-trastuzumab emtansine; DM1-trastuzumab immunoconjugate; Kadcyla; PRO-132365; R3502; RG 3502; RO 5304020; T-DM1; Trastuzumab-DM1; Trastuzumab-DM1 immunoconjugate; Trastuzumab-MCC-DM1; Trastuzumab-MCC-DM1 antibody-drug conjugate; Trastuzumab–SMCC–DM1 conjugate

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genentech; ImmunoGen
  • Developer Chugai Pharmaceutical; Genentech; Memorial Sloan-Kettering Cancer Center; Roche; University College London; University of Miami
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Immunotoxins; Macrolides; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer
  • Phase II Bladder cancer; Lung cancer; Non-small cell lung cancer; Solid tumours; Urogenital cancer
  • Discontinued Gastric cancer

Most Recent Events

  • 14 Jun 2017 Phase-I clinical trials in Breast cancer (Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable, Late-stage disease) in China (IV) (NCT03153163)
  • 03 Jun 2017 Final efficacy and adverse events data from the phase III MARIANNE trial in Breast cancer (Combination therapy, First-line therapy, Metastatic disease) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Primary efficacy and adverse event data from a phase II trial in Non-small cell cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top